Tevogen Bio
Dirigeants
Voir l'organigramme avec ses 15 principaux dirigeants
Biographies les plus recherchées chez Tevogen Bio
- Ryan Saadi, Chairman of the Board and Chief Executive Officer
- Lindee Goh, Director
- Curtis Patton, Director
Changements de dirigeants chez Tevogen Bio
- Tapan Shah, a rejoint l'entreprise comme Head of Investor Relations and Corporate Development (publié le 5 avril 2024).
- Mittul Mehta, a rejoint l'entreprise comme Chief Information Officer and Head of Tevogen.ai (publié le 24 octobre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Tevogen Bio.
Biotechnologie
Tevogen Bio a 2 289 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Delphia Therapeutics vient d'annoncer une levée de fonds de 67 millions de dollars. (publié le 7 mai 2024).
- Karius vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 3 mai 2024).
- Transcarent vient d'annoncer une levée de fonds de 126 millions de dollars. (publié le 2 mai 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Tevogen Bio
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
- Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
- Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
- Tevogen Bio Reports Series A-1 Preferred Stock Investment
- Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
- Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
- Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus
- Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
- Tevogen Bio Announces $8 Million Equity Investment
- Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Tevogen Bio
- Tevogen Bio sur Wikipédia, Google News & Yahoo Finance en 1-click
- Tevogen Bio sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Ryan Saadi 
Appelez Tevogen Bio au +1 267...
